Verily, the life sciences arm of Google's parent company Alphabet, earlierAnnounceA major restructuring and fundraising plan. With its latest round of funding totaling $3 million, Verily not only changed its corporate structure from a Limited Liability Company (LLC) to a Corporation, but also officially changed its name to "Verily Health Inc." The most crucial significance of this change is that parent company Alphabet's stake in the company has fallen below an absolute majority, officially moving from a "controlling" to a controlling stake.Convert to "minority" investorVerily has shifted its core strategy entirely to the hottest field of artificial intelligence (AI).
Alphabet restructures its equity structure with $3 million, taking a backseat.
Verily, formerly known as Google Life Sciences, was officially renamed Verily in 2015 (around the same time Google restructured into Alphabet), becoming one of the group's most iconic "Other Bets" (other forward-looking investments) businesses.
Following its $3 million funding round, Verily is undergoing a major organizational restructuring. By transforming itself into a corporation and changing its name to Verily Health Inc., the company demonstrates a stronger commitment to independent operation and a potential future IPO. With the influx of new capital and the restructuring of its shareholding, Alphabet, while remaining a significant shareholder, no longer holds a controlling stake. This gives Verily's management team greater decision-making flexibility, allowing them to navigate the rapidly changing biomedical market with greater agility.
Say goodbye to medical hardware and fully embrace AI data analytics
Like all technology companies today, Verily Health Inc.'s new chapter will undoubtedly revolve around "artificial intelligence."
Verily Chairman and CEO Stephen Gillett emphasized: "From basic research to clinical care, our customers need solutions that perfectly combine cutting-edge clinical scientific rigor with AI to deliver the next generation of healthcare—a precise and highly personalized medical experience."
Looking back, Verily has invested heavily in various experimental projects, such as developing technology to predict heart disease risk using eye scans and establishing opioid addiction treatment centers. However, in 2025, Verily resolutely...It closed its medical equipment division.In retrospect, this bold move was a strategic step to shed the heavy burden of hardware R&D and concentrate resources entirely on the AI software and medical data analysis market.
